0:15:57 · AJ Rice, UBS · 2027 growth
What underpins the 12% earnings growth target for 2027, and does it depend on Medicaid margin improvement or changes in cost trend assumptions?
Management says it is not relying on any single business or market assumption, pointing to health benefits margin improvement, Carelon growth and operating efficiency from a higher baseline. — Gail Boudreaux
0:17:30 · Andrew Mock, Barclays · Medicaid MLR
Was Medicaid MLR up, down or flat versus last year, and are the better rates prospective or partly out-of-period?
Mark Kay said the 90.6% ratio was favorable to expectations, with Medicaid helped by July 1 rate actions while underlying cost trend stayed elevated but stable. — Mark Kay, Gail Boudreaux
0:19:35 · Justin Lake, Wolfe Research · Medicaid work requirements
How are Medicaid work requirements expected to affect membership, acuity and 2027 state rates?
States are still developing implementation plans, some are building work requirements into 2027 rates, and Elevance is planning for incremental acuity pressure while expecting Medicaid margins to improve. — Felicia Norwood, Mark Kay
0:22:33 · Stephen Baxter, Wells Fargo · Medicaid margin
Why is the Medicaid margin improvement smaller than the improvement in rates, and is incremental investment part of the baseline?
Rates are not fully caught up with underlying costs, cost trend is stable but elevated, and the improvement also depends on targeted medical cost actions. — Mark Kay, Gail Boudreaux
0:25:37 · Lisa Gill, JPMorgan · CarelonRx
What drove CarelonRx's strong quarter, and what are the expectations for pharmacy in the 2027 selling season?
CarelonRx margin reflected solid PBM execution and better dispensing assets, and management cited savings of up to $100 per member per month and about 30% or more fewer emergency room visits for integrated members. — Mark Kay, Gail Boudreaux
0:27:40 · Lance Wilkes, Bernstein · 2027 selling season
How much of Carelon Services growth for 2027 comes from internal versus external contracts, how is the employer selling season going, and what about the new Carelon president?
Carelon Services has new external wins and over 90% retention in most risk solutions, commercial has meaningful wins including returning jumbo employers, and Jeff Park joins as Carelon president. — Mark Kay, Morgan Kendrick, Gail Boudreaux
0:31:54 · Scott Fidel, Goldman Sachs · Commercial pricing
What is the view on commercial cost trend and how is 2027 being priced, including for independent dispute resolution?
Elevance priced 2026 and 2027 for a low double digit cost trend that includes IDR, and says its own IDR experience is consistent with those assumptions. — Mark Kay
0:34:42 · Kevin Fischbeck, Bank of America · Medicaid target
How long will it take Medicaid margins to return to target and what are the biggest variables?
Recovery depends mainly on how fast rates align with cost; the long-term target is 2% to 4% and more detail on 2027 will come in January. — Mark Kay
0:36:25 · Erin Wright, Morgan Stanley · Capital deployment
What does 2027 assume for capital deployment and share buybacks, and is Elevance leaning into specialty pharmacy?
Near-term capital posture is intentionally disciplined with opportunistic buybacks, and specialty is central to CarelonRx, citing a new oncology center of excellence within BioPlus. — Mark Kay
0:38:51 · George Hill, Deutsche Bank · IDR and pricing
Will IDR keep weighing on commercial results, is 2027 priced for margin expansion or maintenance, and what about ACA margins?
Elevance wants IDR reformed, plans stable year-over-year margin in large group fully insured, and says 2027 ACA rates position it to build on this year's progress. — Gail Boudreaux, Mark Kay
0:42:18 · Anne Hines, BofA Securities · ACA acuity
How do ACA disenrollment and the shift toward bronze affect acuity and risk adjustment?
The bronze shift affects the risk adjustment position, but ACA still performs ahead of expectations after incorporating it, and September data informed the accrual. — Mark Kay
0:43:40 · Ben Hendricks, RBC Capital Markets · Medicaid cost actions
What besides rates will drive 2027 Medicaid margin expansion?
Behavioral health oversight, payment integrity analytics, network alignment, and pharmacy and site-of-care actions are expected to contribute a growing share into 2027. — Mark Kay
0:45:36 · Dave Winley, Jefferies · Carelon risk
Will Carelon's risk businesses benefit if cost trend moderates, or stay insulated as they have been?
Carelon is not insulated from cost pressure, but contract structure and clinical programs mean its results do not mirror overall trend, as in behavioral health. — Mark Kay, Gail Boudreaux
0:48:55 · Jason Casorla, Guggenheim Securities · ACA enrollment
Why does year-end ACA membership guidance imply a sequential drop, and how will the exchange market look in 2027?
Fourth quarter allows for attrition above historical levels, and the company expects at least 1.2 million members; it expects the risk pool to take more than one renewal cycle to normalize. — Mark Kay
0:51:06 · Elizabeth Anderson, Evercore ISI · Commercial ASO
As commercial shifts toward ASO, how does Elevance capture share and integrate Carelon?
Elevance sells multiple funding mechanisms, sees large customers returning for integrated solutions, and is offering alternative health plans for lower-cost options down market. — Morgan Kendrick, Gail Boudreaux
0:54:26 · Ryan Langston, TD Cowen · Medicare Advantage margin
Does 2027 earnings growth assume Medicare Advantage returns to target margin, and will commercial risk enrollment contract?
Medicare Advantage margin is expected to improve on at least 2% in 2027 on the path to the 3% to 5% long-term range. — Felicia Norwood
0:55:27 · Whit Mayo, Leerink Partners · ABA therapy
How does Elevance view CMS guidance on ABA therapy and what can it control on spend?
It is focused on medical cost management and AI-enabled payment integrity to spot claim abnormalities while keeping family access to care. — Felicia Norwood